Market Overview

Benzinga's Top Initiations

Share:
Benzinga's Top Initiations
Related ARWR
Deutsche Bank Downgrades Arrowhead, Says 2015 Is The 'Show-Me Year'
Mid-Day Market Update: Foundation Medicine Shares Jump Following Deal With Roche; Crude Oil Slides Over 4%
Related FMI
Stocks That Battle Cancer Were The Best-Performing Biotechs In January
State Of The Union Lights Up Biotech
Poor Pipeline Productivity Has Left Roche More Vulnerable (Seeking Alpha)

Analysts at Piper Jaffray initiated coverage on shares of Arrowhead Research (NASDAQ: ARWR) with an “overweight” rating. The target price for Arrowhead Research is set to $12. Arrowhead Research's shares closed at $7.87 on Friday.

Analysts at Goldman Sachs initiated coverage on shares of Foundation Medicine (NASDAQ: FMI) with a “neutral” rating. The target price for Foundation Medicine is set to $33. Foundation Medicine's stock closed at $33.99 on Friday.

JP Morgan initiated coverage on shares of Premier (NASDAQ: PINC) with an “overweight” rating. The target price for Premier is set to $36. Premier's shares closed at $31.66 on Friday.

Morgan Stanley initiated coverage on shares of Ophthotech (NASDAQ: OPHT) with an “overweight” rating. The target price for Ophthotech is set to $56. Ophthotech's shares closed at $29.25 on Friday.

Latest Ratings for ARWR

DateFirmActionFromTo
Jan 2015Deutsche BankDowngradesBuyHold
Oct 2014RBC CapitalDowngradesOutperformSector Perform
Oct 2014Deutsche BankMaintainsBuy

View More Analyst Ratings for ARWR
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings

 

Related Articles (ARWR + FMI)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional